Brighton Jones LLC Acquires 6,847 Shares of Incyte Corporation $INCY

Brighton Jones LLC raised its holdings in shares of Incyte Corporation (NASDAQ:INCY) by 22.0% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 37,963 shares of the biopharmaceutical company’s stock after purchasing an additional 6,847 shares during the period. Brighton Jones LLC’s holdings in Incyte were worth $3,220,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of Incyte by 0.7% in the 2nd quarter. Vanguard Group Inc. now owns 20,135,393 shares of the biopharmaceutical company’s stock worth $1,371,220,000 after purchasing an additional 137,570 shares in the last quarter. AQR Capital Management LLC lifted its stake in Incyte by 21.8% during the 2nd quarter. AQR Capital Management LLC now owns 8,201,455 shares of the biopharmaceutical company’s stock valued at $558,519,000 after acquiring an additional 1,465,286 shares during the period. Geode Capital Management LLC lifted its position in Incyte by 3.3% during the second quarter. Geode Capital Management LLC now owns 4,347,731 shares of the biopharmaceutical company’s stock valued at $294,899,000 after purchasing an additional 139,740 shares during the period. LSV Asset Management boosted its holdings in Incyte by 6.2% in the second quarter. LSV Asset Management now owns 3,861,831 shares of the biopharmaceutical company’s stock worth $262,991,000 after purchasing an additional 223,857 shares during the last quarter. Finally, Invesco Ltd. raised its stake in Incyte by 7.3% during the 2nd quarter. Invesco Ltd. now owns 3,401,018 shares of the biopharmaceutical company’s stock valued at $231,609,000 after buying an additional 232,268 shares during the last quarter. Hedge funds and other institutional investors own 96.97% of the company’s stock.

Insider Activity at Incyte

In other news, EVP Steven H. Stein sold 20,105 shares of the company’s stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $102.51, for a total value of $2,060,963.55. Following the sale, the executive vice president directly owned 63,129 shares of the company’s stock, valued at $6,471,353.79. This represents a 24.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Sheila A. Denton sold 598 shares of the firm’s stock in a transaction dated Tuesday, November 4th. The stock was sold at an average price of $101.36, for a total value of $60,613.28. Following the sale, the executive vice president directly owned 26,569 shares in the company, valued at approximately $2,693,033.84. This trade represents a 2.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 88,318 shares of company stock worth $8,708,893 in the last quarter. 17.80% of the stock is owned by insiders.

Analyst Ratings Changes

INCY has been the subject of several research reports. Wall Street Zen raised shares of Incyte from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Guggenheim raised Incyte from a “neutral” rating to a “buy” rating and set a $125.00 target price on the stock in a report on Monday, November 3rd. Wells Fargo & Company boosted their price target on Incyte from $97.00 to $116.00 and gave the company an “overweight” rating in a report on Monday, December 8th. Royal Bank Of Canada lifted their price objective on Incyte from $81.00 to $84.00 and gave the company a “sector perform” rating in a research report on Wednesday, October 29th. Finally, JPMorgan Chase & Co. raised their target price on shares of Incyte from $73.00 to $89.00 and gave the stock a “neutral” rating in a research note on Thursday, October 9th. Eight equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Incyte presently has a consensus rating of “Hold” and an average price target of $99.07.

Key Incyte News

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Japan regulatory wins expand commercial footprint — Japan approved Zynyz (retifanlimab) for first‑line advanced anal cancer and approved Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma. These approvals support additional revenue and market expansion in a major market. Article Title Article Title
• Neutral Sentiment: Momentum/analyst note: a Zacks piece flagged a recent ~5.5% rally and above‑average volume but warned that recent estimate revisions may limit near‑term upside — supportive of interest but not a clear buy signal on its own. Article Title
• Negative Sentiment: Insider selling: EVP and other insiders reported large sales — Incyte EVP sold about $5.25M of stock, and director/officer Thomas Tray disclosed sales totaling 3,374 shares across Dec. 18–19 (~$98–$100 per share). Large, concentrated insider sales can signal near‑term selling pressure or raise governance questions. Article Title SEC Filing

Incyte Stock Down 1.9%

Shares of NASDAQ INCY opened at $100.71 on Tuesday. The company has a market cap of $19.77 billion, a P/E ratio of 16.87, a PEG ratio of 0.70 and a beta of 0.81. The firm has a 50-day simple moving average of $98.53 and a two-hundred day simple moving average of $85.09. Incyte Corporation has a 1 year low of $53.56 and a 1 year high of $109.28. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.20 and a quick ratio of 3.13.

Incyte (NASDAQ:INCY) last announced its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $2.26 EPS for the quarter, beating the consensus estimate of $1.65 by $0.61. Incyte had a return on equity of 26.56% and a net margin of 24.69%.The firm had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.26 billion. During the same quarter last year, the firm posted $1.07 earnings per share. The business’s revenue for the quarter was up 20.0% on a year-over-year basis. Research analysts anticipate that Incyte Corporation will post 4.86 earnings per share for the current year.

Incyte Company Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.